Bavarian Nordic names its new leader Read in browser

Thank you for reading, dupa dupackia! basic Subscription UPGRADE

M T W Thu F 17 September, 2026

Real innovation is getting harder to spot. The Endpoints 11 is our read on the private companies clearing a rising bar, revealed at a gala dinner with the founders, investors and editors behind the list. Save on your gala pass with code ELEVEN26.

presented by Pac­ing the Jour­ney: A Frame­work to Com­mer­cial Readi­ness

news Lilly-backed Orbis does up to $1.4B macrocycle deal with Novo Bavarian Nordic names Tarja Stenvall as new CEO Roche turns to Dualitas to find new bispecific approaches for immunology

Sep 16 2:00 pm ET Beyond ICD codes: Unlocking rare disease insights with genomics and claims-based data sponsored by GeneDx Sep 22 12:00 pm ET The future of drug pricing: Medicare negotiation, MFN models & beyond sponsored by ADVI Oct 15 1:00 pm ET Insights into Polycystic Kidney Disease: The Potential of Clinicogenomic Data sponsored by Natera Oct 20 11:00 am ET Intelligent oversight and orchestration: How mission control is redefining R&D decision-making sponsored by ZS Oct 22 11:00 am ET A new model for clinical research – Expanding community trial access sponsored by Parexel

AI has stopped being a question and started being an answer. Remaking workforces, AI-derived molecules into the clinic, catching record capital against sharpening doubt. What does it mean for biopharma? Find out, join us.

in case you missed it 1. Drug companies have cooperated with lawmaker’s probe of China trial sites 2. FDA faces questions on 'America First' provisions in latest user fee agreement 3. Mice with human brain cells open a new testing ground for drugmakers to study disease 4. Novo, Anthropic sign deal to apply AI to drug discovery 5. News Briefing Gilead reaches HIV PrEP agreements; Hong Kong investigates Cloudbreak IPO 6. Novartis' TREM2 drug fails Phase 2 ALS trial 7. Skyhawk says its Huntington’s drug improved symptoms in extension to Phase 1/2 trial 8. Sling gets $123M for Phase 3 trial of ex-Astellas drug in thyroid eye disease 9. Fed raises interest rates for first time since 2023, defying Trump as inflation mounts NBC News